Colonization Versus Carriage of Clostridium difficile

Infectious Disease Clinics of North America

Volumn 29, Issue 1, 2015, Pages 13-28

  Donskey, Curtis J ^a   Kundrapu, Sirisha ^b   Deshpande, Abhishek ^c  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antibiotic; Clostridium difficile; Colonization; Transmission

Indexed keywords

CEFIXIME; CEFPODOXIME; METRONIDAZOLE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

BACTERIAL COLONIZATION; BACTERIAL SHEDDING; BACTERIAL STRAIN; BACTERIUM CARRIER; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE CARRIER; FECES ANALYSIS; GENOTYPE; HEALTH CARE FACILITY; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION CONTROL; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; STOMACH ACID; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FECES; GASTROINTESTINAL TRACT; HETEROZYGOTE; ISOLATION AND PURIFICATION; MICROBIOLOGY; TRANSMISSION;

CARRIER STATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FECES; GASTROINTESTINAL TRACT; HEALTH FACILITIES; HUMANS;

EID: 84922847191     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.11.001     Document Type: Review

References (66)

1. Shim J.K., Johnson S., Samore M.H., et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998, 351:633-636.
2. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. NEngl J Med 1989, 320:204-210.
3. Clabots C.R., Johnson S., Olson M.M., et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. JInfect Dis 1992, 166:561-567.
4. Samore M.H., DeGirolami P.C., Tlucko A., et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994, 18:181-187.
5. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. NEngl J Med 2000, 342:390-397.
6. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. NEngl J Med 2011, 365:1693-1703.
7. Jinno S., Kundrapu S., Guerrero D.M., et al. Potential for transmission of Clostridium difficile by asymptomatic acute care patients and long-term care facility residents with prior C. difficile infection. Infect Control Hosp Epidemiol 2012, 33:638-639.
8. Sethi A.K., Al-Nassir W.N., Nerandzic M.M., et al. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol 2010, 31:21-27.
9. Alasmari F., Seiler S.M., Hink T., et al. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014, 59:216-222.
10. Brazier J.S., Fitzgerald T.C., Hosein I., et al. Screening for carriage and nosocomial acquisition of Clostridium difficile by culture: a study of 284 admissions of elderly patients to six general hospitals in Wales. JHosp Infect 1999, 43:317-319.
11. Curry S.R., Muto C.A., Schlackman J.L., et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 2013, 57:1094-1102.
12. Eyre D.W., Griffiths D., Vaughan A., et al. Asymptomatic Clostridium difficile colonisation and onward transmission. PLoS One 2013, 8:e78445.
13. Gerding D.N., Olson M.M., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986, 146:95-100.
14. Guerrero D.M., Becker J.C., Eckstein E.C., et al. Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. JHosp Infect 2013, 85:155-158.
15. Hung Y.P., Tsai P.J., Hung K.H., et al. Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS One 2012, 7:e42415.
16. Johnson S., Clabots C.R., Linn F.V., et al. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990, 336:97-100.
17. Leekha S., Aronhalt K.C., Sloan L.M., et al. Asymptomatic Clostridium difficile colonization in a tertiary care hospital: admission prevalence and risk factors. Am J Infect Control 2013, 41:390-393.
18. Riggs M.M., Sethi A.K., Zabarsky T.F., et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007, 45:992-998.
19. Simor A.E., Bradley S.F., Strausbaugh L.J., et al. Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002, 23:696-703.
20. Marciniak C., Chen D., Stein A.C., et al. Prevalence of Clostridium difficile colonization at admission to rehabilitation. Arch Phys Med Rehabil 2006, 87:1086-1090.
21. Kato H., Kita H., Karasawa T., et al. Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. JMed Microbiol 2001, 50:720-727.
22. Ozaki E., Kato H., Kita H., et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. JMed Microbiol 2004, 53:167-172.
23. Rea M.C., O'Sullivan O., Shanahan F., et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. JClin Microbiol 2012, 50:867-875.
24. Galdys A.L., Curry S.R., Harrison L.H. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. Expert Rev Anti Infect Ther 2014, 12:967-980.
25. Chachaty E., Depitre C., Mario N., et al. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrob Agents Chemother 1992, 36:2009-2013.
26. Freter R., Brickner H., Fekete J., et al. Survival and implantation of Escherichia coli in the intestinal tract. Infect Immun 1983, 39:686-703.
27. Villano S.A., Seiberling M., Tatarowicz W., et al. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 2012, 56:5224-5229.
28. Rao A., Jump R.L., Pultz N.J., et al. Invitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother 2006, 50:3901-3904.
29. Deshpande A., Pant C., Pasupuleti V., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012, 10:225-233. [meta-analysis].
30. Naggie S., Miller B.A., Zuzak K.B., et al. Acase-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011, 124(276):e271-e277.
31. Nerandzic M.M., Pultz M.J., Donskey C.J. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother 2009, 53:4133-4137.
32. Cunningham R., Mustoe E., Spiller L., et al. Acidified nitrite: a host defence against colonization with C. difficile spores?. JHosp Infect 2014, 86:155-157.
33. Vesper B.J., Jawdi A., Altman K.W., et al. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab 2009, 10:84-89.
34. Sorg J.A., Sonenshein A.L. Bile salts and glycine as cogerminants for Clostridium difficile spores. JBacteriol 2008, 190:2505-2512.
35. Adams D.A., Riggs M.M., Donskey C.J. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 2007, 51:2674-2678.
36. Pultz N.J., Stiefel U., Subramanyan S., et al. Mechanisms by which anaerobic microbiota inhibit the establishment in mice of intestinal colonization by vancomycin-resistant Enterococcus. JInfect Dis 2005, 191:949-956.
37. Rousseau C., Poilane I., De Pontual L., et al. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis 2012, 55:1209-1215.
38. Wilson K.H., Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 1988, 56:2610-2614.
39. Ng K.M., Ferreyra J.A., Higginbottom S.K., et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013, 502:96-99.
40. Theriot C.M., Koenigsknecht M.J., Carlson P.E., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 2014, 5:3114.
41. Lawley T.D., Clare S., Walker A.W., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8:e1002995.
42. Rolfe R.D. Role of volatile fatty acids in colonization resistance to Clostridium difficile. Infect Immun 1984, 45:185-191.
43. Su W.J., Waechter M.J., Bourlioux P., et al. Role of volatile fatty acids in colonization resistance to Clostridium difficile in gnotobiotic mice. Infect Immun 1987, 55:1686-1691.
44. Giel J.L., Sorg J.A., Sonenshein A.L., et al. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 2010, 5:e8740.
45. Wilson K.H. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. JClin Microbiol 1983, 18:1017-1019.
46. Banerjee P., Merkel G.J., Bhunia A.K. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 2009, 1:8.
47. Buffie C.G., Pamer E.G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013, 13:790-801.
48. Jiang Z.D., DuPont H.L., Garey K., et al. Acommon polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol 2006, 101:1112-1116.
49. Louie T.J., Cannon K., Byrne B., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012, 55(Suppl 2):S132-S142.
50. Sunkesula V.C., Kundrapu S., Jury L.A., et al. Potential for transmission of spores by patients awaiting laboratory testing to confirm suspected Clostridium difficile infection. Infect Control Hosp Epidemiol 2013, 34:306-308.
51. Abujamel T., Cadnum J.L., Jury L.A., et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One 2013, 8:e76269.
52. Centers for Disease Control and Prevention (CDC) Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012, 61:157-162.
53. Owens R.C., Donskey C.J., Gaynes R.P., et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S19-S31.
54. Donskey C.J., Sunkesula V.C., Jencson A.L., et al. Utility of a commercial PCR assay and a clinical prediction rule for detection of toxigenic Clostridium difficile in asymptomatic carriers. JClin Microbiol 2014, 52:315-318.
55. Jury L.A., Sitzlar B., Kundrapu S., et al. Outpatient healthcare settings and transmission of Clostridium difficile. PLoS One 2013, 8:e70175.
56. Kim K.H., Fekety R., Batts D.H., et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. JInfect Dis 1981, 143:42-50.
57. Johnson S., Homann S.R., Bettin K.M., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992, 117:297-302.
58. Bolton R.P., Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986, 27:1169-1172.
59. Edlund C., Barkholt L., Olsson-Liljequist B., et al. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 1997, 25:729-732.
60. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEngl J Med 2011, 364:422-431.
61. Kundrapu S., Sunkesula V., Jury I., et al. Arandomized trial of soap and water hand wash versus alcohol hand rub for removal of Clostridium difficile spores from hands of patients. Infect Control Hosp Epidemiol 2014, 35:204-206.
62. Jury L.A., Guerrero D.M., Burant C.J., et al. Effectiveness of routine patient bathing to decrease the burden of spores on the skin of patients with Clostridium difficile infection. Infect Control Hosp Epidemiol 2011, 32:181-184.
63. Nerandzic M.M., Rackaityte E., Jury L.A., et al. Novel strategies for enhanced removal of persistent Bacillus anthracis surrogates and Clostridium difficile spores from skin. PLoS One 2013, 8:e68706.
64. Kallen A.J., Thompson A., Ristaino P., et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009, 30:264-272.
65. Johnson S., Samore M.H., Farrow K.A., et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. NEngl J Med 1999, 341:1645-1651.
66. Fowler S., Webber A., Cooper B.S., et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. JAntimicrob Chemother 2007, 59:990-995.